---
title: "Incyte's new CEO outlines growth plan as Jakafi patent cliff nears"
description: "Incyte Corp's new CEO, Bill Meury, has unveiled a growth strategy focused on drug development and capital allocation as the company approaches the patent expiration of its leading drug, Jakafi. Follow"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250634498.md"
published_at: "2025-07-29T15:39:41.000Z"
---

# Incyte's new CEO outlines growth plan as Jakafi patent cliff nears

> Incyte Corp's new CEO, Bill Meury, has unveiled a growth strategy focused on drug development and capital allocation as the company approaches the patent expiration of its leading drug, Jakafi. Following his first earnings call, Incyte's shares rose nearly 8%. The company raised its 2025 Jakafi sales forecast to $3 billion-$3.05 billion, with Q2 sales reaching $763.8 million. Incyte is also banking on its vitiligo treatment, Opzelura, which saw a 35% sales increase. Meury remains open to strategic deals to enhance growth.

(Rewrites throughout to add CEO comments, analyst comment and updates share movement)

By Kamal Choudhury

July 29 (Reuters) - Incyte Corp’s (INCY.O) new chief executive, Bill Meury, outlined a growth strategy on Tuesday focused on accelerating drug development and prudent capital allocation, as the company faces the looming patent expiration of its top-selling blood cancer drug, Jakafi.

The drugmaker’s shares rose nearly 8%.

Speaking on his first earnings call since taking the helm in June, Meury said Incyte is preparing to transition to new growth drivers ahead of Jakafi’s 2028 patent cliff.

“We intend to build a comprehensive plan for acceleration that goes beyond just filling a revenue gap,” Meury told analysts, emphasizing the company would take “a fresh look at this business, including our R&D productivity, operating expenses and capital allocation.”

Earlier in the day, Incyte raised its 2025 Jakafi sales forecast range to $3 billion to $3.05 billion, from $2.95 billion to $3 billion.

Sales of Jakafi climbed 8% to $763.8 million in the quarter ended June 30 from a year ago, above the $754.4 million analysts had expected.

The company is banking on Opzelura, its cream for vitiligo and mild-to-moderate atopic dermatitis, as a key growth driver.

Opzelura’s sales surged 35% to $164.5 million in the quarter, beating estimates of $160.4 million.

Total revenue for the quarter rose to $1.22 billion, surpassing analysts’ forecast of $1.15 billion.

On an adjusted basis, Incyte earned $1.57 per share, exceeding estimates of $1.47.

Despite the company’s focus on capital discipline, it remained open to deal opportunities.

Meury said strategically sourced, appropriately priced and well executed deals could add value, and that the company would be on the lookout for “de-risked pre-revenue or revenue stage opportunities.”

Cantor analyst Eric Schmidt described Meury as “a seasoned biotech leader with a commercial background and a sparkly track record of past M&A exits.”

“It sounds like Bill is singing from the same song book that we have advocated.”

### Related Stocks

- [INCY.US - Incyte](https://longbridge.com/en/quote/INCY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 因塞特醫療的執行副總裁兼首席醫療官 Steven H. Stein 報告了出售普通股的情況 | 史蒂文·H·斯坦（Steven H. Stein），因塞特醫療（Incyte Corporation）的執行副總裁兼首席醫學官，報告了普通股的出售。完整的文件可以通過提供的鏈接獲取。此消息由公共技術公司生成，僅供參考，不應被視為財務或法律建 | [Link](https://longbridge.com/en/news/271836874.md) |
| 財捷的期權活動顯示出可能的看漲反轉信號 | 財捷期權活動信號顯示潛在的看漲反轉 | [Link](https://longbridge.com/en/news/275935163.md) |
| 突發觀點 - 白宮在關税泥潭中越陷越深 | 美國眾議院以 217 票對 214 票投票反對共和黨領導層阻止對特朗普對加拿大和墨西哥關税的挑戰。這一決定可能使民主黨能夠提出撤銷這些關税的決議。情況因一宗最高法院案件、尋求退款的公司以及共和黨內部對關税日益增長的不滿而變得複雜，這可能對共 | [Link](https://longbridge.com/en/news/275635316.md) |
| 百威英博首席財務官 Fernando Tennenbaum 表示，希望 2026 年在成本方面會更加正常，我們看到進一步擴展利潤率的機會 | 百威英博首席財務官費爾南多·特嫩鮑姆：希望 2026 年在成本方面會是一個更正常的年份，我們看到進一步擴大利潤空間的機會 | [Link](https://longbridge.com/en/news/275819045.md) |
| Biltmore Family Office LLC 減持了 NVIDIA Corporation $NVDA 的股份 | Biltmore Family Office LLC 在第三季度減少了對英偉達公司（NASDAQ: NVDA）9.1% 的持股，目前持有 29,694 股，價值 5,541,000 美元。其他投資者，包括 October Effect Lt | [Link](https://longbridge.com/en/news/275999991.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.